Get the Stockscreener App
2.81
1.06%
-0.03
After Hours:
2.81
Anixa Biosciences Inc stock is traded at $2.81, with a volume of 111.67K.
It is down -1.06% in the last 24 hours and down -11.08% over the past month.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
See More
Previous Close:
$2.84
Open:
$2.86
24h Volume:
111.67K
Relative Volume:
0.40
Market Cap:
$93.80M
Revenue:
-
Net Income/Loss:
$-12.48M
P/E Ratio:
-7.2051
EPS:
-0.39
Net Cash Flow:
$-7.93M
1W Performance:
+2.18%
1M Performance:
-11.08%
6M Performance:
-7.57%
1Y Performance:
-10.51%
1-Day Range:
$2.74
$2.98
1-Week Range:
$2.69
$3.035
52-Week Range:
$2.331
$5.4566
Anixa Biosciences Inc Stock (ANIX) Company Profile
Name
Anixa Biosciences Inc
Sector
Industry
Phone
408-708-9808
Address
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE
Compare ANIX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANIX
Anixa Biosciences Inc
|
2.81 | 94.80M | 0 | -12.48M | -7.93M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Anixa Biosciences Inc Stock (ANIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-21-25 | Initiated | Maxim Group | Buy |
| Dec-23-22 | Initiated | Chardan Capital Markets | Buy |
| Apr-12-21 | Initiated | H.C. Wainwright | Buy |
Anixa Biosciences Inc Stock (ANIX) Latest News
Anixa Biosciences CEO Calls 2026 “Pivotal” as Breast Cancer Vaccine, Ovarian CAR-T Advance - MarketBeat
ANIX: Pivotal data from advanced cancer trials and fiscal discipline set the stage for a transformative 2026 - TradingView
Anixa reports promising survival data in ovarian cancer CAR-T trial - Investing.com Canada
Anixa reports promising survival data in ovarian cancer CAR-T trial By Investing.com - Investing.com South Africa
Anixa Biosciences (ANIX) Reports Positive Data in Ovarian Cancer CAR-T Trial - GuruFocus
Anixa Advances Ovarian Cancer CAR-T With Higher Dosing - TipRanks
Anixa Biosciences reports encouraging patient survival observations in ovarian cancer CAR-T trial - marketscreener.com
Anixa Biosciences Reports Encouraging Patient Survival Observations In Ovarian Cancer Car-T Trial - TradingView
ANIX: Major dose escalation approved after strong survival and safety data in ovarian cancer CAR-T trial - TradingView
Anixa Biosciences Reports Encouraging Data in Ovarian Cancer CAR-T Trial - TradingView
Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation - PR Newswire
EXCLUSIVE: Anixa Biosciences' Ovarian Cancer Drug Candidate Shows Longer Survival With No Major Safety Issues - Benzinga
Here's Why We're Not Too Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation - Yahoo Finance
ANIX: Analyst Maintains "Buy" Rating and $10 Price Target | ANIX Stock News - GuruFocus
D. Boral Capital Reiterates "Buy" Rating for Anixa Biosciences (NASDAQ:ANIX) - MarketBeat
Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization - BioSpace
Anixa Biosciences Secures United States Adopted Names Council Ap - GuruFocus
Anixa Biosciences (ANIX) CAR-T Therapy Receives USAN Approval - GuruFocus
Experimental ovarian cancer CAR-T earns official U.S. drug name - Stock Titan
Market Recap: Can Anixa Biosciences Inc keep up with sector leadersJuly 2025 Final Week & Daily Stock Trend Watchlist - baoquankhu1.vn
Anixa Biosciences Inc (NASDAQ:ANIX) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Insider Buying: Arnold Baskies Acquires Additional Shares of Ani - GuruFocus
Anixa Biosciences (NASDAQ:ANIX) Director Arnold Baskies Acquires 10,000 Shares - MarketBeat
Anixa Biosciences director Baskies buys $30,400 in stock By Investing.com - Investing.com UK
Anixa Biosciences director Baskies buys $30,400 in stock - Investing.com
Anixa Biosciences receives Mexican patent for breast cancer vaccine By Investing.com - Investing.com Australia
Institution Moves: Does Anixa Biosciences Inc have declining or rising EPSTrade Exit Report & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Anixa Biosciences Receives Notice of Allowance from Mexican Institute of Industrial Property (IMPI) for Patent Covering Breast Cancer Vaccine Technology - The AI Journal
Anixa Biosciences rises after Mexico approves patent for breast cancer vaccine - TradingView
Anixa Biosciences (ANIX) Secures Mexican Patent for Breast Cance - GuruFocus
Anixa Biosciences receives Mexican patent for breast cancer vaccine - Investing.com
Dividend Watch: Is Anixa Biosciences Inc gaining market shareMarket Performance Recap & Community Verified Trade Signals - baoquankhu1.vn
New Highs: Whats Anixa Biosciences Incs historical returnQuarterly Risk Review & Technical Analysis for Trade Confirmation - baoquankhu1.vn
ANIX: Initiating Coverage; Anixa's T-Cell Innovations Show Breakthrough Potential in Solid Tumors - Smartkarma
Anixa Biosciences Inc (NASDAQ:ANIX) Short Interest Update - Defense World
Can Anixa Biosciences Inc. maintain its current growth rateEarnings Trend Report & Accurate Technical Buy Alerts - bollywoodhelpline.com
AI Stocks: What hedge funds are buying NUWECPI Data & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Anixa Biosciences (NASDAQ:ANIX) Rating Increased to Hold at Wall Street Zen - MarketBeat
ANIX: D. Boral Capital Maintains Buy Rating with $10 Price Targe - GuruFocus
Anixa Biosciences (NASDAQ:ANIX) Issues Earnings Results, Meets Expectations - MarketBeat
Breakouts Watch: Will Anixa Biosciences Inc stock attract ESG investorsWeekly Stock Recap & Free Risk Controlled Daily Trade Plans - Bộ Nội Vụ
Anixa Biosciences : Annual Report for Fiscal Year Ending October 31, 2025 (Form 10-K) - marketscreener.com
Anixa Biosciences Inc SEC 10-K Report - TradingView — Track All Markets
Published on: 2026-01-11 17:33:32 - Улправда
ETF Watch: Will Anixa Biosciences Inc. stock deliver better than expected guidanceJuly 2025 Short Interest & Risk Adjusted Buy and Sell Alerts - Улправда
Why Anixa Biosciences Inc. stock appeals to dividend seekersWeekly Earnings Recap & Stock Timing and Entry Methods - Улправда
What catalysts could drive Anixa Biosciences Inc. stock higherWeekly Trade Recap & Verified Entry Point Detection - Улправда
Why analysts upgrade Anixa Biosciences Inc. stockStock Buyback Updates & Low Risk Trading Portfolio - Улправда
Anixa Biosciences Inc (NASDAQ:ANIX) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Anixa Biosciences (ANIX) Expected to Announce Quarterly Earnings on Friday - MarketBeat
Anixa Biosciences Inc Stock (ANIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):